文献速递系统性红斑狼疮

对称二甲基精氨酸是系统性红斑狼疮抗Sm自身抗体的核心抗原决定簇

Symmetrical dimethylarginine as the central antigenic determinant of anti-Smith autoantibodies in systemic lupus erythematosus.
PubMed 文献 · Ann Rheum Dis · 2026-07-10

该研究探讨抗Sm抗体对对称二甲基精氨酸(sDMA)的特异性和交叉反应性,采用ELISA、竞争性ELISA和亲和纯化等方法,发现抗Sm+ SLE患者中约90%的抗Sm IgG识别sDMA残基且不依赖Sm序列背景,并能交叉识别包括EBNA1在内的多种sDMA修饰病毒表位,提示分子模拟机制可能参与抗Sm+ SLE的免疫耐受突破。

要点

  • 抗Sm+ SLE患者中约90%的抗Sm IgG靶向sDMA残基,而非Sm蛋白序列本身。
  • sDMA flanking氨基酸对抗Sm IgG识别有适度影响,但sDMA是核心决定簇。
  • 抗Sm IgG可交叉识别sDMA修饰的病毒表位包括EBNA1,提示分子模拟机制。

核心结论

  • 抗Sm IgG大多数靶向sDMA残基而不依赖其Sm序列背景,代表一种原型抗翻译后修饰反应。
  • 这些抗体高度交叉反应,可识别多种sDMA修饰靶点包括天然病毒sDMA表达表位。
  • sDMA修饰病毒蛋白的分子模拟可能参与抗Sm+ SLE患者免疫耐受突破。

研究设计与样本

  • 研究采用ELISA在SLE患者和健康供者中检测抗Sm IgG对含sDMA或未修饰精氨酸肽的特异性和交叉反应性。
  • 采用竞争性ELISA和亲和纯化确定抑制和交叉反应。
  • 采用含EB病毒淋巴母细胞系裂解物Western blot检测抗Sm IgG对内源性EBNA1的识别。

主要发现

  • 抗Sm+ SLE患者识别sDMA残基 regardless of 肽氨基酸序列,sDMA侧翼氨基酸对识别有适度影响。
  • 靶向sDMA的IgG占抗Sm抗体库的总体大多数(约90%)。
  • 抗Sm IgG在SmD3108-122和多个含sDMA病毒来源表位之间高度交叉反应,包括全长EBNA1。

关键数值与推荐

  • SLE中最特异的自身抗体反应存在于20%至30%的患者中,靶向Smith(Sm)蛋白复合物。
  • 抗Sm抗体识别含精氨酸翻译后修饰sDMA的线性Sm来源B细胞表位。
  • 约90%的抗Sm抗体库为靶向sDMA的IgG。

临床怎么用

  • 抗Sm抗体检测阳性时,其靶抗原核心为sDMA修饰而非Sm蛋白序列,解读结果需考虑交叉反应性。
  • 抗Sm+ SLE患者中抗Sm IgG可识别sDMA修饰的病毒表位,提示分子模拟可能参与疾病发生。
  • sDMA可作为抗Sm抗体相关检测和机制研究的核心抗原决定簇。

局限性

  • 研究采用ELISA、竞争性ELISA和Western blot等体外方法,未涉及临床干预或纵向随访。
  • 病毒sDMA表位与疾病发生的因果关系未在研究中直接验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease causing multiorgan damage. The most specific autoantibody response in SLE, present in 20% to 30% of patients, targets the Smith (Sm)-protein complex and has been shown to recognise a linear Sm-derived B cell epitope containing a posttranslational modification (PTM) of arginine termed symmetrical dimethyl arginine (sDMA). As autoantibodies to other PTM-modified proteins are often promiscuous, we aimed to determine the specificity and cross-reactivity of anti-Sm antibodies. METHODS: Specificity and promiscuity/cross-reactivity of anti-Sm immunoglobulin G (IgG) were measured using enzyme-linked immunosorbent assay in patients with SLE and healthy donors using peptides containing either sDMA or unmodified arginine. Inhibition and cross-reactivity were determined using competitive enzyme-linked immunosorbent assay and affinity purification. Recognition of endogenous Epstein-Barr nuclear antigen 1 (EBNA1) by anti-Sm IgG was performed using a Western blot of lysates of Epstein-Barr virus-bearing lymphoblastoid cell lines. RESULTS: The sDMA residue is recognised by patients with anti-Sm+ SLE regardless of the peptide amino acid sequence, with a modest impact of amino acids flanking sDMA on recognition. Most notably, IgGs targeting sDMA comprise the overall majority (∼90%) of the anti-Sm antibody repertoire and are highly cross-reactive between SmD3108-122 and several sDMA-containing viral-derived epitopes, including full-length (EBNA1). CONCLUSION: Our data implicate that the majority of anti-Sm IgGs target the sDMA residue irrespective of its Sm-context, thus representing a prototypic anti-PTM response. These antibodies are highly promiscuous, recognising several sDMA-modified targets, including naturally occurring viral sDMA-expressing epitopes. These findings suggest a new mechanism by which molecular mimicry of sDMA-modified viral proteins could contribute to a breach of tolerance in patients with anti-Sm+ SLE.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. van Vliet LC, Dorjée AL, van der Heide M, et al. Symmetrical dimethylarginine as the central antigenic determinant of anti-Smith autoantibodies in systemic lupus erythematosus. Ann Rheum Dis. 2026. PMID: 42431785. doi:10.1016/j.ard.2026.06.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。